A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genentech; Roche
- 16 Jul 2018 Planned End Date changed from 1 Mar 2019 to 19 Feb 2019.
- 16 Jul 2018 Planned primary completion date changed from 1 Mar 2019 to 19 Feb 2019.
- 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.